Groowe Groowe / Newsroom / PFE
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

PFE News

Pfizer Inc.

Pfizer Responds to Delaware Chancery Court Ruling

businesswire.com
PFE

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

businesswire.com
PFE

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

businesswire.com
PFE MTSR

Pfizer Addresses Proposal for Metsera

businesswire.com
PFE NVO MTSR

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

prnewswire.com
IOBT NVS BCAX PFE

Precision Oncology Approaches Drive $312B Market Transformation

prnewswire.com
GTBP NRIX GRAL CCCC PFE GTBP NRIX GRAL CCCC PFE

ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain

businesswire.com
PFE

ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir

businesswire.com
PFE

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

businesswire.com
PFE

Pfizer Declares Fourth-Quarter 2025 Dividend

businesswire.com
PFE